SOFT TISSUE SARCOMA • Soft Tissues Include: • Muscles • Tendons • Fat • Blood Vessels • Lymph Vessels • Nerves • Tissues Around Joints
Total Page:16
File Type:pdf, Size:1020Kb
NAACCR Webinar Series 2017-2018 1/11/18 COLLECTING CANCER DATA: GIST/SARCOMA 2017‐2018 NAACCR WEBINAR SERIES Q&A • Please submit all questions concerning webinar content through the Q&A panel. • Reminder: • If you have participants watching this webinar at your site, please collect their names and emails. • We will be distributing a Q&A document in about one week. This document will fully answer questions asked during the webinar and will contain any corrections that we may discover after the webinar. 2 Uterus 1 NAACCR Webinar Series 2017-2018 1/11/18 Fabulous Prizes 3 AGENDA • Overview • Epi Moment • Quiz 1 • Staging • Bone • Soft Tissue • GIST • Treatment • Quiz 2 • Case Scenarios 4 Uterus 2 NAACCR Webinar Series 2017-2018 1/11/18 SARCOMA ANATOMY 5 SOFT TISSUE SARCOMA • Soft tissues include: • Muscles • Tendons • Fat • Blood vessels • Lymph vessels • Nerves • Tissues around joints 6 Uterus 3 NAACCR Webinar Series 2017-2018 1/11/18 SOFT TISSUE SARCOMA • Over 50 different types • Angiosarcoma – blood vessels or lymph vessels; following radiation • Undifferentiated pleomorphic sarcoma – most often in arms or legs (previously malignant fibrous histiocytoma MFH) • Spindle cell sarcoma – descriptive name based on the appearance of the cells • Liposarcoma – fat cells; most frequently seen 7 SOFT TISSUE SARCOMA • Pleomorphic dermal sarcoma • Atypical Fibroxanthoma (AFX) • Arise in sun‐damaged skin • Arise in sun‐damaged skin • Head, Neck, Scalp • Ear, Nose, Forehead, Cheek • Negative: S100, Multiple CK, • Negative: S100, multiple CK, Desmin, CD34 Desmin, CD34 • Behavior likely more aggressive • Behavior is almost invariably a but limited follow up due to benign behavior with only rare patient advanced age at local recurrence presentation 8 Uterus 4 NAACCR Webinar Series 2017-2018 1/11/18 SOFT TISSUE SARCOMA • Question • What is the appropriate histology code for a final diagnosis or undifferentiated pleomorphic sarcoma and/or pleomorphic sarcoma, undifferentiated? Does the Other Sites MP/H Rule H17 apply in this case, which results in coding higher histology 8805/3? Or does the “undifferentiated” statement only refer to grade, which results in coding histology to 8802/3 (pleomorphic sarcoma)? 9 ANSWER • SINQ 20160044 • Assign 8802/34 to pleomorphic cell sarcoma/undifferentiated pleomorphic sarcoma. Pleomorphic is more important than undifferentiated when choosing the histology code in this case. Undifferentiated can be captured in the grade code. 10 Uterus 5 NAACCR Webinar Series 2017-2018 1/11/18 SARCOMA • 2018 Histology – New Terms • 8571/3 Carcinoma with chondroid differentiation (C50._) Carcinoma with osseous differentiation (C50._) Metaplastic carcinoma with chondroid differentiation (C50._) Metaplastic carcinoma with osseous differentiation (C50._) 11 SARCOMA • 2018 Histology – New Terms • 8801/3 Undifferentiated spindle cell sarcoma • 8802/3 Undifferentiated pleomorphic sarcoma • 8803/3 Undifferentiated round cell sarcoma • 8804/3 Undifferentiated epithelioid sarcoma • 8805/3 Undifferentiated uterine sarcoma • 8830/3 Undifferentiated high‐grade pleomorphic sarcoma 12 Uterus 6 NAACCR Webinar Series 2017-2018 1/11/18 OSTEOSARCOMA • Most common malignant bone tumor • Arise from osteoblasts • Typically occurs in long bones • Mutation in TP53 are most common • Distant metastasis occur in ~20% • Lung is most common site 13 OSTEOSARCOMA • Periosteum • 2 layers • Fibrous connective tissue • Inner osteogenic • Medullary cavity • Bone marrow https://seer.cancer.gov/tools/ssm/musculoskel.pdf 14 Uterus 7 NAACCR Webinar Series 2017-2018 1/11/18 SOFT TISSUE SARCOMA GRADE • FNCLCC grading system • Differentiation • Necrosis • Mitotic rate • Histologic Grade: GX Grade cannot be assessed G1 FNCLCC grade score of 2 or 3 G2 FNCLCC grade score of 4 or 5 G3 FNCLCC grade score of 6, 7, or 815 GIST ANATOMY 16 Uterus 8 NAACCR Webinar Series 2017-2018 1/11/18 WHAT IS GIST? • Rare type of soft tissue sarcoma • Develop in muscle layer of gut rather than mucosa • Grow outward (exophytic) • Described as a distinct entity in 1998 • Umbrella term for most mesenchymal tumors of stomach and intestine • Most tumors historically called leiomyosarcoma are now classified as GISTs 17 GIST • Interstitial cells of Cajal • “Pacemaker cells” • Sends signals to move food and liquid through system (peristalsis) http://www.gistsupport.org/media/Understanding%20Pathology%20Report/Fig‐1‐ 400pix.jpg 18 Uterus 9 NAACCR Webinar Series 2017-2018 1/11/18 ONCOGENIC MUTATIONS • ~85% of GIST contain oncogenic mutations in one of two receptor tyrosine kinases • KIT‐Mutant GIST • PDGFRA (Platelet‐derived Growth Factor Receptor Alpha) • Wild Type GIST • ~12‐15% GIST contain no genetic mutation of KIT or PDGFRA 19 TUMOR LOCATION Stomach 60% Small Intestine 30% Rectum 3% Colon 1‐2% Esophagus <1% Omentum/Mese Rare ntery 20 Uterus 10 NAACCR Webinar Series 2017-2018 1/11/18 GIST • How do you determine if a GIST is malignant i.e. reportable? • GIST, NOS is a borderline tumor (/1) • If your state or facility requires collection of these GISTs, you should follow their requirements • Don’t determine reportability based on staging • AJCC staging forms are used on all GISTs 21 Theme Song: The Skeleton Dance COLLECTING CANCER DATA: SARCOMA EPI MOMENT: RECINDA SHERMAN JANUARY 11, 2018 Uterus 11 NAACCR Webinar Series 2017-2018 1/11/18 EPIDEMIOLOGY OF SARCOMAS • Large grouping of distinct cancers • 50+ distinct histologies; putative mesenchymal origin • Combined & studied as group • Rare in adults (<2%); Top 5 for Pedi (21%) • Majority soft tissue (87%); malignant bone (13%) • Soft: muscles, joints, fat, nerves, deep skin, blood vessels • Bone: commonly in cartilage • Prognosis generally poor; esp soft • Delayed diagnosis: arise anywhere, lack of specific symptoms • No population based screening • Poor survival adults; better for pedi Figures from: Burningham, Zachary, Mia Hashibe, Logan Spector, and Joshua D. Schiffman. "The Epidemiology of Sarcoma." Clinical Sarcoma Research (2012). BioMed Central Ltd. Web. 10 Feb. 2016. 23 Sarcoma (Soft), 0‐19, CiNA 2014 PEDIATRIC SARCOMAS (SOFT) 12% Rhabdomyosarcomas 36% • Rhabdomyosarcoma – most common soft tissue for peds Fibrosarcomas, peripheral nerve & other fibrous • Skeletal muscle Other specified soft tissue 40% sarcomas • Unspecified soft tissue 50% occur <10; slightly more common in males 12% sarcomas • Often presents as painless mass; risk factor Li‐Fraumeni syndrome • 5 year survival 70%; dependent upon location, stage, and histology—often lymph node involvement • Embryonal better prognosis than alveolar subtype; 20% present metastatic with 5 year survival 30‐40% vs 80% for local • Other Sarcomas (Soft), Rate per 1,000,000, CiNA 2014 • Fibrosarcoma – historically 2/3rds of sarcomas 1.4 1.2 1.2 • now 12% due to better classification (proportion changed but not risk) 1 0.8 0.5 • Liposarcoma – often large tumors; common among adults but <5% of ped sarcomas 0.6 0.4 0.4 th • Synovial sarcoma –4 most common; 2x more common in males 0.2 0.1 0.1 0 • origin mesenchymal not synovium; largely genetic • Malignant peripheral nerve sheath tumors – grouped into Brain CNS category for Epi • Alveolar Soft Part Sarcoma (ASPS) – rare, slow growing; generally mets at dx • Mesenchymoma – rare but highly aggressive 24 Uterus 12 NAACCR Webinar Series 2017-2018 1/11/18 PEDIATRIC SARCOMAS (BONE) • Osteosarcoma – most common • Generally on edges of “long” bones; 2nd most common location upper arm near shoulder • Surgery & Chemo • Chondrosarcomas • Ewing Family – 10‐15% of bone sarcomas in peds Sarcomas (Bone), Rate per 1,000,000, CiNA 2014 • Ewing sarcoma, extraosseous Ewing, PNET, Askin) 10 9.3 9 • Impacts teens; responsive to radiotherapy 8 7 Sarcomas (Bone), 0‐19, CiNA 2014 6 5.1 5 3% 6% 4 3.0 3 2 1 0.3 0.5 0.2 32% 0 55% 4% Osteosarcomas Chondrosarcomas Ewing Family Other specified malignant bone tumors Unspecified malignant bone tumors 25 RISK FACTORS • Varied causes; distinct disease; limited studies & understanding • Environmental, genetic (synergistic) • Genetic • Age: Soft: Rate high <5 for soft, lower but steady increase 6‐49; 50+ high; Bone: Rate stable across ages; Rate high in YA (osteosarcoma, Ewing) • Race: Ewing (9x more common white vs black); but soft tissue higher for blacks • Hx of hernia ‐ Ewing sarcoma (children) • Growth “spurts” – osteosarcoma (children) • Genetic syndromes (Li‐Fraumeni; neurofibromatosis/von Recklinghausen dx, retinoblastoma) • Non currently described for Ewing but likely genetic • Environmental • HIV+ for KS (but HHV8 is causal, HIV & EBV)) • Radiation exposure ‐ Bone cancer; Tx and atomic (Japanese) • Occupational exposures ‐‐herbicides (soft tissue) 26 Uterus 13 NAACCR Webinar Series 2017-2018 1/11/18 THE GIST ON G.I.S.T.h/t Brad Wohler, FCDS • 2001 ICD‐O‐3 specific code • Rare, digestive tract soft tissue sarcoma • Adult cancer; 50+ • Used to believe origin was nerve or muscle cells • Now understood to arise from interstitial cells of Cajal (ICC) or precursor—the “pacemakers” of digestion; occur from esoph to anus but over ½ in stomach • Moving away from “benign” designation = increase rates but not risk GIST, over time (CiNA 1995‐2014) 1 0.8 APC 7.8%* 0.6 0.4 0.2 0 27 QUESTIONS? QUIZ 1 28 Uterus 14 NAACCR Webinar Series 2017-2018 1/11/18 STAGING SUMMARY STAGE AJCC 29 SUMMARY STAGE 2000 & 2018 30 Uterus 15 NAACCR Webinar Series 2017-2018 1/11/18 SUMMARY STAGE 2000‐MUSCULOSKELETAL SYSTEM • Bones, joints, and articular cartilage • C40.0‐C40.3, C40.8‐C40.9, C41.0‐C41.4, C41.8‐C41.9 • Peripheral nerves and autonomic nervous